GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe

26.3.2026 14:30:00 EET | Business Wire | Press release

GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI.

Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by the expanding use of highly effective antitumor therapies - including chemotherapy, radiotherapy and targeted therapies - many of which are associated with cardiovascular toxicities. Global studiesⁱ show that heart-related complications are now the second leading cause of death in cancer survivors, after the cancer itself, accounting for up to 10% of mortality. Despite the broad recognition of cardiotoxicity as a major clinical challenge, evidence-based approaches to its management remain restricted. Limited understanding of the biological mechanisms underlying cardiotoxicity, a lack of reliable biomarkers, and the absence of effective preventive strategies, heighten patient risks and place growing pressure on healthcare systems, particularly in Europe’s aging population.

Across Europe, the COMPASS partners aim to improve the cardiovascular health of cancer patients and survivors through a comprehensive, end-to-end, patient centered clinical pathway, enabling timely intervention and safer continuation of cancer therapy while reducing the risk of cardiovascular complications. By fostering multidisciplinary collaboration, regulatory alignment, as well as patient awareness and engagement, COMPASS aims to ensure that clinically meaningful innovations are effectively translated into routine healthcare practice within Europe.

“King’s College London is looking forward to providing academic leadership and scientific coordination to COMPASS, harnessing the consortium expertise across cardiology, oncology, molecular science, big data and AI to address the increasing challenge in cardiotoxicity in cancer care,” said Steve Archibald, Professor in Molecular Imaging, School of Biomedical Engineering & Imaging Sciences, King’s College London. “We aim to promote integrated care models to drive widespread adoption across healthcare systems.”

The program intends to predict cardiotoxicity risk, detect cardiovascular disease at an earlier stage, coordinate and personalize cancer and cardiovascular care, supporting patients in daily life, and managing long-term cardiovascular effects of cancer treatment. To achieve this, COMPASS will focus on the following areas:

Identification of novel biomarkers for cardiotoxicity diagnosis and risk stratification: advancing the early detection of cardiotoxicity through innovative molecular imaging, advanced cardiac imaging techniques, and multi-omics biomarker discovery, which integrates genetic, molecular, and metabolic data to enable earlier, more precise disease prediction and diagnosis.
AI-enabled predictive and clinical decision support tools: leveraging AI to integrate real-world data, imaging, non-imaging, biomarkers and wearable data into predictive models and decision-support tools for personalized care in clinical settings.
Improved care delivery and enhanced patient engagement: promoting integrated care pathways, patient education and stakeholder engagement to ensure equitable access, long-term follow-up and patient-centred outcomes.

“This initiative is well positioned to enable patient-centered cancer care that takes cardiotoxicity risk into account, supports the early detection of cardiotoxic side-effects, and promotes long-term heart health for oncology patients,” said Eigil Samset, General Manager, Cardiology Solutions at GE HealthCare and COMPASS Industry Lead. “We are honored to play an integral part as industry lead in this multidisciplinary collaboration which brings together the expertise of leading European academic, clinical, industry, and patient advocacy groups. By developing an AI-powered, integrated care pathway that connects oncologists and cardiologists in clinical practice, this collaboration has the potential to further improve cancer survival by tackling cardiovascular-related morbidity.”

The project is co-funded under the Horizon Europe framework, as part of IHI which is a public-private partnership between the European Union and the European life science industries. The Joint Undertaking (IHI JU) under grant agreement Nr. #101253264 receives support from the European Union’s Horizon Europe research and innovation program and from COCIR, EFPIA, Europa Bío, MedTech Europe, Vaccines Europe and COMPASS contributing partners. The grant agreement was signed on March 25, 2026, and runs through the next five years. For more information and for the full list of consortium members, please visit the IHI website.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.

ⁱ MDPI. Cardiotoxicity of Chemotherapy: A Multi-OMIC Perspective January 8. 2025. https://www.mdpi.com/2039-4713/15/1/9

View source version on businesswire.com: https://www.businesswire.com/news/home/20260326630305/en/

Contacts

GE HealthCare Media Contact:
Karin Dalsin
M +1 612-219-2855
Karin.Dalsin@gehealthcare.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CSG Named a Leader in the Gartner® Magic Quadrant™ for Customer Journey Analytics & Orchestration26.3.2026 17:30:00 EET | Press release

Rising customer expectations for connected, relevant, and effortless interactions are making journey analytics and orchestration critical to delivering consistent, personalized experiences that earn loyalty. As CSG® (NASDAQ: CSGS) helps businesses to meet and exceed those expectations, the company today announced that CSG has been named a Leader in the 2026 Gartner® Magic Quadrant™ for Customer Journey Analytics & Orchestration. The evaluation assessed the company’s overall Completeness of Vision and Ability to Execute. “It’s not enough to understand the customer – businesses must act on that knowledge in real time and prove the value of every customer interaction,” said Katie Costanzo, President, Customer Experience, CSG. “That requires a unified system that turns real-time data into clear decisions, measurable outcomes, and experiences customers can trust. I am incredibly proud that CSG has been named a Leader in the inaugural Gartner Magic Quadrant for Journey Analytics & Orchestrat

India: The Up-and-Coming Solar Market26.3.2026 17:27:00 EET | Press release

Solar energy expansion is booming worldwide. India, in particular, is seeing rapid growth thanks to state funding programs, tax incentives, subsidies and green loans from banks. In 2025, 37.5 gigawatts were added – a 50 percent increase from the previous year. The 2026 budget provides for a deployment of 45 to 50 gigawatts, allowing the most densely populated country to become the second largest solar market in the world. Intersolar Europe will shine a spotlight on the south Asian country from June 23–25 in Munich. India is an up-and-coming market for the international PV industry. There will be numerous events where visitors can learn about the market, new business opportunities and the structure of new supply chains. The exhibition will take place as part of The smarter E Europe, Europe’s largest alliance of exhibitions for the energy industry. More than 100,000 visitors and 2,800 exhibitors from all over the world are expected to attend. This press release features multimedia. View

Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 15:00:00 EET | Press release

Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap widens, confidence erodes and competitive advantage is lost. Orchestrated Planning removes decision latency by harmonizing data, people, processes and agentic capabilities to help organizations mo

Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 15:00:00 EET | Press release

Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expansion plans, strategic drivers, and regulatory challenges.1 CSC’s report Navigating U.S. Market Entry: Insights, Risks, and Opportunities for Global Businesses details the results. The research highlights strong forward momentum toward U.S. expansion. In addition to the 45% planning to establish an entity within the next 12 months, a further 27% s

Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 14:30:00 EET | Press release

Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial in patients with plaque psoriasis, atopic dermatitis, and skin aging (photo-aged skin). The recently completed Phase 1 clinical trial, conducted in the European Union, was designed to assess the safety, tolerability, clinical effects, plasma bioavailability, and pharmacodynamics of topical RLS-1496—the first-ever GPX4 (selective glutathione peroxidase 4) modulator to be studied in human trials, and the first specifically targeting cellular rejuvenation, an area of great interest to the scientific community as a new therapeutic pathway. The study met its primary endpoint, with RLS-1496 also demonstrating early signs of efficacy. Preliminary Trial Results RLS-1496 was well-tolerated,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom